THE OVARIAN ACTION OF INTERLEUKIN-1 IS RECEPTOR-MEDIATED - REVERSAL BY A NATURALLY-OCCURRING INTERLEUKIN-1 RECEPTOR ANTAGONIST

被引:10
|
作者
KOKIA, E [1 ]
BENSHLOMO, I [1 ]
ADASHI, EY [1 ]
机构
[1] UNIV MARYLAND,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD ENDOCRINOL,BALTIMORE,MD 21201
关键词
INTERLEUKIN-1; INTERLEUKIN-1 RECEPTOR ANTAGONIST; OVARY; GRANULOSA; PROSTAGLANDINS;
D O I
10.1016/S0015-0282(16)57314-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To address indirectly the possibility that the ovarian action(s) of interleukin (IL)-1 are receptor mediated and to re-examine the recently reported proposition that the naturally occurring IL-1 receptor antagonist (IL-1ra) may in fact act in the capacity of mixed IL-1 receptor agonist/antagonist. Design: In vitro treatment of isolated granulosa cell (GC) and whole ovarian dispersates of rat origin. Results: Treatment of GC from immature rats with increasing concentrations of IL-1ra (10 to 5,000 ng/mL) proved without effect on either the basal or FSH (100 ng/mL)-supported accumulation of P. Likewise, cellular viability (as assessed by conversion of 3-[4,5-dimethylthiazol-2-yl]-2-5 diphenyltetrazolium bromide to spectrophotometrically detectable formazan) remained unaltered. However, the concomitant addition of increasing concentrations of IL-1ra (10 to 5,000 ng/mL) yielded dose-dependent reversal of the 10 ng/mL IL-1 beta-mediated inhibition of the FSH-supported accumulation of P. Similarly, the ability of IL-1 beta to exert a dose-dependent (0 to 30 ng/mL) antigonadotropic effect was attenuated progressively given the concurrent presence of increasing concentrations (1,000 and 5,000 ng/mL) of IL-1ra. Although treatment of whole ovarian dispersates with 10 ng/mL IL-1 beta resulted in a 5.4-fold increase in the accumulation of prostaglandin (PG)E(2), this effect too was all but eliminated after the concomitant addition of 5 mu g/mL IL-1ra. Conclusions: These observations support the nontoxic nature of IL-1ra, confirm its lack of agonistic activity, validate its utility as an experimental probe, and suggest that neither the basal nor the FSH-stimulated accumulation of P are subject to regulation by endogenously produced GC-derived IL-1-like activity. Moreover, these observations suggest that the ability of IL-1 beta to inhibit the gonadotropin-supported accumulation of P and to increase PGE(2) accumulation is receptor-mediated.
引用
收藏
页码:176 / 181
页数:6
相关论文
共 50 条
  • [21] INTERLEUKIN-1 RECEPTOR ANTAGONIST ACTIVITY OF A HUMAN INTERLEUKIN-1 INHIBITOR
    HANNUM, CH
    WILCOX, CJ
    AREND, WP
    JOSLIN, FG
    DRIPPS, DJ
    HEIMDAL, PL
    ARMES, LG
    SOMMER, A
    EISENBERG, SP
    THOMPSON, RC
    NATURE, 1990, 343 (6256) : 336 - 340
  • [22] INTERLEUKIN-1 RECEPTOR ANTAGONIST - EFFECTIVENESS AGAINST INTERLEUKIN-1 FEVER
    COCEANI, F
    LEES, J
    REDFORD, J
    BISHAI, I
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1992, 70 (12) : 1590 - 1596
  • [23] Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus
    Chang, DM
    IMMUNOLOGICAL INVESTIGATIONS, 1997, 26 (5-7) : 649 - 659
  • [24] Predictors of interleukin-1β and interleukin-1 receptor antagonist in infant saliva
    Miller, Elizabeth M.
    AMERICAN JOURNAL OF HUMAN BIOLOGY, 2021, 33 (03)
  • [25] Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease
    Cominelli, F
    Pizarro, TT
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 : 49 - 53
  • [26] Interleukin-1β, Interleukin-1 Receptor Antagonist, and Soluble Interleukin-1 Receptor Type II Secretion in Chronic Fatigue Syndrome
    Joseph G. Cannon
    Jonathan B. Angel
    Leslie W. Abad
    Edouard Vannier
    Maria D. Mileno
    Laura Fagioli
    Sheldon M. Wolff
    Anthony L. Komaroff
    Journal of Clinical Immunology, 1997, 17 : 253 - 261
  • [27] INTERLEUKIN-1 AND ITS NATURALLY-OCCURRING ANTAGONIST IN PERITONEAL-DIALYSIS PATIENTS
    MOUTABARRIK, A
    NAKANISHI, I
    NAMIKI, M
    TSUBAKIHARA, Y
    CLINICAL NEPHROLOGY, 1995, 43 (04) : 243 - 248
  • [28] ROLE OF INTERLEUKIN-1 AND THE THERAPEUTIC POTENTIAL OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN SEPSIS
    FISHER, CJ
    OPAL, SM
    LOWRY, SF
    SADOFF, JC
    LABRECQUE, JF
    DONOVAN, HC
    LOOKABAUGH, JL
    LEMKE, J
    PRIBBLE, JP
    STROMATT, SC
    VIGERS, GP
    RUSSELL, DA
    THOMPSON, RC
    CIRCULATORY SHOCK, 1994, 44 (01) : 1 - 8
  • [29] INHIBITION BY INTERLEUKIN-1 RECEPTOR ANTAGONIST OF INVIVO ACTIVITIES OF INTERLEUKIN-1 IN MICE
    MENGOZZI, M
    BERTINI, R
    SIRONI, M
    GHEZZI, P
    LYMPHOKINE AND CYTOKINE RESEARCH, 1991, 10 (05): : 405 - 407
  • [30] Expression of interleukin-1α and interleukin-1 receptor antagonist in gingival keratinocytes.
    Yang, QB
    Izumi, Y
    Sueda, T
    JOURNAL OF DENTAL RESEARCH, 1999, 78 (05) : 1122 - 1122